|

Immune checkpoint inhibitor Clinical Trials

14 actively recruiting trials across 4 locations

▲ +1 trial since May 2026

Also known as: 1, AK104, Atezolizumab, Avelumab, Cadonilimab +10 more

Pipeline

Phase 2: 2Phase 3: 2Phase 4: 1Phase 1/2: 3

Top Sponsors

  • University of Washington1
  • Universitaire Ziekenhuizen KU Leuven1
  • Sun Yat-sen University1
  • Shanghai Chest Hospital1
  • Peking Union Medical College Hospital1

Indications

Other10 trials

A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC
Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma
Biomarkers in Immunotherapy of Melanoma
N/A
Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
Phase 3
ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI
Phase 2
Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer
Phase 2
Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
Phase 3
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Phase 1/2

Scottsdale, Arizona1 trial

Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors

Honor Health Research Institute

Phase 1/2

Portland, Oregon1 trial

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

OHSU Knight Cancer Institute

Phase 4

Houston, Texas1 trial

Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer

M D Anderson Cancer Center

Seattle, Washington1 trial

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.